Multiple Myeloma – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Powered by
Access in-depth insight and stay ahead of the market
Multiple Myeloma Cell Therapy Market Report Overview
The total market value for the 15M, which includes both cell therapies and established/traditional MM therapies was $25.7 billion in 2021 The market growth will be attributed to the established CAR-T agents such as Abecma and Carvykt.
Multiple Myeloma Cell Therapy Market Outlook, 2021-2031 ($ Billion)
Buy the Full Report to Know More about the Multiple Myeloma Cell Therapy Market Forecast
The MM cell therapy market research report offers a comprehensive insight into the market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market.
Market Size (2021) | $25.7 billion |
Forecast Period | 2021-2031 |
Key Regions | · APAC
· Europe · Middle East · North America |
Leading Players | · Johnson & Johnson
· Teva Pharmaceutical Industries Ltd · F. Hoffmann-La Roche Ltd · Novartis AG · Bristol Myers Squibb Co |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Multiple Myeloma Cell Therapy Market Dynamics
Patients may prefer more convenient therapies that do not require IV administration, which is one of the factors hampering the MM cell therapy market growth. However, the large pipeline of CAR-T agents in late-phase clinical trials is expected to gain approvals in later-line settings and capture significant market share due to high unmet need in these settings in the coming years.
Multiple Myeloma Cell Therapy Market Analysis by Treatment
- The approval of CAR-T cell therapies such as Abecma and Carvykti has provided viable treatment options for patients requiring drugs in later-line settings.
- The launch of Carvykti in China for use in 3L+ settings will address an unmet need. These marketed CAR-T cell therapies aim to move into earlier lines of therapy. Meanwhile, Abecma may address the needs of patients with high-risk cytogenetics as it is currently in a trial for later-line settings.
Buy the Full Report for More Insights into the Multiple Myeloma Cell Therapy Market Treatment
Multiple Myeloma Cell Therapy Market Segmentation by Regions
North America had the highest sales in 15MM in the MM cell therapy market.
A few of the key regions in the market are APAC, Europe, Middle East, and North America.
Multiple Myeloma Cell Therapy Market Analysis by Regions, 2021 (%)
Buy the Full Report for More Regional Insights into the Multiple Myeloma Cell Therapy Market
Multiple Myeloma Cell Therapy Market - Competitive Landscape
The clinical pipeline for cell therapies in MM has candidates from many different companies, largely small-to-medium sized US- or China-based biotechs and large global pharma companies. Moreover, Carvykti was approved based on a Phase I/II trial, and the number of ongoing Phase I–III trials could indicate a myriad of approvals over the forecast period.
A few of the major players in the Multiple Myeloma Cell Therapy market are:
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd
- Hoffmann-La Roche Ltd
- Novartis AG
- Bristol Myers Squibb Co
Multiple Myeloma Cell Therapy Market Analysis by Companies
Buy the Full Report to Know More about Companies in the Multiple Myeloma Cell Therapy Market
Multiple Myeloma Cell Therapy Country Outlook (Value, $ Billion, 2021-2031)
- APAC
- Europe
- Middle East
- North America
Reasons to Buy
The report includes:
- What is the target patient pool for cell and gene therapies in each cancer indication?
- Which patient groups are more likely to receive these therapies?
- What does the cell & gene therapy clinical-stage pipeline look like in each cancer indication?
- What is the anticipated breakdown between autologous and allogeneic cell therapies?
- When will cell & gene therapies launch in each market?
- What is the total market value projected for the forecast end, in 2031?
Key Players
BMSJ&J
Nanjing IASO Biotherapeutics
Arcellx
CARsgen Therapeutics
Table of Contents
Frequently asked questions
-
What was the MM cell therapy market size across the 15M in 2021?
The MM cell therapy market size across the 15M was valued at $25.7 billion in 2021.
-
Which region had the highest sales in the 15M MM cell therapy market in 2021?
North America held the highest sales in the MM cell therapy market across the 8MM in 2021.
-
Who are the leading players operating in the MM cell therapy market?
A few of the major players in the MM cell therapy market are Johnson & Johnson, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd, Novartis AG, and Bristol Myers Squibb Co. among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.